BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24833327)

  • 1. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
    Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
    Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.
    Tse HN; Raiteri L; Wong KY; Yee KS; Ng LY; Wai KY; Loo CK; Chan MH
    Chest; 2013 Jul; 144(1):106-118. PubMed ID: 23348146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study.
    Stav D; Raz M
    Chest; 2009 Aug; 136(2):381-386. PubMed ID: 19447919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review.
    Fowdar K; Chen H; He Z; Zhang J; Zhong X; Zhang J; Li M; Bai J
    Heart Lung; 2017; 46(2):120-128. PubMed ID: 28109565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
    Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
    Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes.
    Zhang JQ; Zhang JQ; Liu H; Zhao ZH; Fang LZ; Liu L; Fu WP; Shu JK; Feng JG; Dai LM
    Int J Chron Obstruct Pulmon Dis; 2015; 10():917-23. PubMed ID: 25999707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetylcysteine in patients with COPD exacerbations associated with increased sputum.
    Ayfer Aytemur Z; Baysak A; Ozdemir O; Köse T; Sayiner A
    Wien Klin Wochenschr; 2015 Apr; 127(7-8):256-61. PubMed ID: 25595117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
    Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
    Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
    Decramer M; Rutten-van Mölken M; Dekhuijzen PN; Troosters T; van Herwaarden C; Pellegrino R; van Schayck CP; Olivieri D; Del Donno M; De Backer W; Lankhorst I; Ardia A
    Lancet; 2005 Apr 30-May 6; 365(9470):1552-60. PubMed ID: 15866309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I-II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China.
    Tian H; Zhou Y; Tang L; Wu F; Deng Z; Lin B; Huang P; Wei S; Zhao D; Zheng J; Zhong N; Ran P
    Trials; 2020 Sep; 21(1):780. PubMed ID: 32917271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
    Tse HN; Tseng CZ
    Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease.
    Kasielski M; Nowak D
    Respir Med; 2001 Jun; 95(6):448-56. PubMed ID: 11421501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of oral N-acetylcysteine on COPD patients with microsatellite polymorphism in the heme oxygenase-1 gene promoter.
    Zhang JQ; Zhang JQ; Fang LZ; Liu L; Fu WP; Dai LM
    Drug Des Devel Ther; 2015; 9():6379-87. PubMed ID: 26674585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Xia QK; Gao Y; Zhong NS;
    COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
    Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
    Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis.
    Shen Y; Cai W; Lei S; Zhang Z
    COPD; 2014 Jun; 11(3):351-8. PubMed ID: 24378052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD.
    Pela R; Calcagni AM; Subiaco S; Isidori P; Tubaldi A; Sanguinetti CM
    Respiration; 1999; 66(6):495-500. PubMed ID: 10575333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.